Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Rheumatology
Erschienen in: Clinical Rheumatology 5/2024

22.03.2024 | ORIGINAL ARTICLE

Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Qianqian Dai, Yanfeng Zhang, Qian Liu, Chijin Zhang

Erschienen in: Clinical Rheumatology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To summarize and analyze the results of published randomized controlled trials of tofacitinib for the treatment of chronic plaque psoriasis and psoriatic arthritis(PsA) and discuss its efficacy and safety.

Patients and methods

An exhaustive systematic search encompassing PubMed, Cochrane, Embase, and Web of Science databases was conducted up to July 2023. Studies eligible for inclusion were analyzed, organized using Review Manager version 5.4.1 (Cochrane Collaboration, Oxford, UK) and STATA 15.0 version (Stata Corp, College Station, TX, USA) software.

Results

A total of six articles, covering 1393 patients (844 treated with tofacitinib and 549 with placebo), were included. The foundational characteristics of tofacitinib and placebo group showed similarity, except for age and Dermatology Life Quality Index (DLQI) score, especially in the context of chronic plaque psoriasis. It is noteworthy that we discovered tofacitinib exhibited a significant impact on Psoriasis Area and Severity Index 75 (PASI75) response, Physician’s Global Assessment (PGA) response, and adverse events (AEs) in cases of chronic plaque psoriasis. Similarly, tofacitinib demonstrated substantial influence on American College of Rheumatology 20/50 (ACR20/50) response, PASI75 response, as well as alterations in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score, Health Assessment Questionnaire-Disability Index (HAQ-DI) Score, Dactylitis Severity Score (DSS), and Leeds Enthesitis Index (LEI) Score in the context of psoriatic arthritis (PsA). Nevertheless, there was no statistically significant impact of tofacitinib on serious adverse events (SAEs) in chronic plaque psoriasis, as well as on both adverse events (AEs) and SAEs in psoriatic arthritis (PsA).

Conclusions

A comprehensive analysis revealed that tofacitinib has a positive effect on addressing skin and joint symptoms, as well as improving the quality of life for patients with chronic plaque psoriasis and psoriatic arthritis (PsA). However, the safety of the drug’s long-term usage even requires further validation.
Key Points
• In 6 analyses involving a total of 1393 patients, tofacitinib exhibits positive effect on the treatment of both chronic plaque psoriasis and psoriatic arthritis (PsA).
• Although dose-based subgroup analyses have demonstrated effectiveness. Some studies indicate that the 5-mg dose (twice daily) may not show an effect due to the failure of non-inferiority trials comparing tofacitinib with placebo. Therefore, caution is required when interpreting its effectiveness. On the other hand, the 10-mg dose (BID) has been associated with an increase in adverse events and serious adverse events, and is recommended to be used with caution in patients with cardiovascular or uveitis risk factors.
• Tofacitinib has efficacy in comorbid psychiatric disorders (depression, anxiety, or Alzheimer’s disease) and inflammatory bowel disease (ulcerative colitis), but patients with comorbid renal insufficiency, hepatic dysfunction, osteoporosis, cardiovascular disease, or uveitis may need to be moderated or avoided with tofacitinib.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945PubMedCrossRef
2.
Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 157:68–73PubMedCrossRef
3.
Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
4.
Levine D, Gottlieb A (2009) Evaluation and management of psoriasis: an internist’s guide. Med Clin North Am 93:1291–1303PubMedCrossRef
5.
Mease P, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52(1):1–19PubMedCrossRef
6.
Yang Q, Qu L, Tian H et al (2011) Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol 25:1409–1414PubMedCrossRef
7.
Wei JC-C, Shi L-H, Huang J-Y et al (2000) Epidemiology and medication pattern change of psoriatic diseases in Taiwan from 2000 to 2013: a nationwide, population-based cohort study. J Rheumatol 2018(45):385–392
8.
Chopra A, Lin H-Y, Navarra SV et al (2021) Rheumatoid arthritis management in the APLAR region: perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. Int J Rheum Dis 24:1106–1111PubMedCrossRef
9.
Lahiri M, Santosa A, Teoh LK et al (2017) Use of complementary and alternative medicines is associated with delay to initiation of disease-modifying anti-rheumatic drug therapy in early inflammatory arthritis. Int J Rheum Dis 20:567–575PubMedCrossRef
10.
Stern RS, Nichols KT, Vakeva LH (1997) Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA) The PUVA Follow-Up Study. N Engl J Med 336:1041–45PubMedCrossRef
11.
Studniberg HM, Weller P (1993) PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 29:1013–1022PubMedCrossRef
12.
Hsu S, Papp KA, Lebwohl MG et al (2012) Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 148:95–102PubMedCrossRef
13.
Weger W (2010) Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 160:810–820PubMedPubMedCentralCrossRef
14.
Pathirana D, Ormerod AD, Saiag P et al (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(suppl 2):1–70PubMedCrossRef
15.
Dubois DS, Pouliot R (2013) Promising new treatments for psoriasis. Sci World J 2013:980419
16.
Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674PubMedCrossRef
17.
Lebwohl MG, Bachelez H, Barker J et al (2014) Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70:871–881PubMedCrossRef
18.
Yeung H, Wan J, Van Voorhees AS et al (2013) Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 68:64–72PubMedCrossRef
19.
Naldi L, Griffiths CE (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597–615PubMedCrossRef
20.
Gniadecki R, Kragballe K, Dam TN, Skov L (2011) Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 164:1091–1096PubMedCrossRef
21.
22.
de Vlam K, Gottlieb AB, Mease PJ (2014) Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol 94:627–634PubMedCrossRef
23.
Mease P, Hall S, FitzGerald O et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537–1550PubMedCrossRef
24.
Gladman D et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536PubMedCrossRef
25.
Nash P, Coates LC, Fleishaker D et al (2021) Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol 3:e270–e283PubMedCrossRef
26.
27.
28.
Tsai YC, Tsai TF (2016) A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol 151(4):412–431 (Epub 2016 Feb 18)PubMed
29.
Leng X et al (2023) Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open 9:e002559PubMedPubMedCentralCrossRef
30.
31.
32.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef
33.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Res ed) 315(7109):629–634CrossRef
34.
Bachelez H et al (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386:552–561PubMedCrossRef
35.
Papp KA et al (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 74:841–850PubMedCrossRef
36.
Zhang J et al (2017) The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 88:36–45PubMedCrossRef
37.
Ishizaki M, Muromoto R, Akimoto T et al (2014) Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 26(5):257–267PubMedCrossRef
38.
39.
Caso F, Costa L, Chimenti MS, Navarini L, Punzi L (2019) Pathogenesis of psoriatic arthritis. Crit Rev Immunol 39(5):361–377PubMedCrossRef
40.
Marasca C, Ruggiero A, Napolitano M et al (2020) May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses 143:109853PubMedPubMedCentralCrossRef
41.
Caso F, Costa L, Triggianese P et al (2023) Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs 32(5):361–371PubMedCrossRef
42.
Tomura M, Honda T, Tanizaki H, Otsuka A, Egawa G, Tokura Y, Waldmann H, Hori S, Cyster JG, Watanabe T, Miyachi Y, Kanagawa O, Kabashima K (2010) Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 120(3):883–893
43.
Gray EE, Ramírez-Valle F, Xu Y, Wu S, Wu Z, Karjalainen KE, Cyster JG (2013) Deficiency in IL-17-committed Vγ4(+) γδ T cells in a spontaneous Sox13-mutant CD45.1(+) congenic mouse substrain provides protection from dermatitis. Nat Immunol 14:584–592PubMedPubMedCentralCrossRef
44.
45.
Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D (2024) Tofacitinib efficacy in patients with rheumatoid arthritis and probable depression/anxiety: post hoc analysis of phase 3 and 3b/4 randomized controlled trials. Rheumatol Ther 11(1):35–50. https://​doi.​org/​10.​1007/​s40744-023-00612-7
46.
47.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616–624PubMedCrossRef
48.
Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Eng J Med 376:1723–1736CrossRef
49.
Kapoor T, Bathon J (2018) Renal manifestations of rheumatoid arthritis. Rheum Dis Clin North Am 44(4):571–584PubMedCrossRef
50.
Mardani M, Mohammadshahi J, Abolghasemi S, Teimourpour R (2023) Drug-induced liver injury due to tofacitinib: a case report. J Med Case Rep 17(1):97PubMedPubMedCentralCrossRef
51.
Batteux B, Bennis Y, Bodeau S, Masmoudi K, Hurtel-Lemaire AS, Kamel S, Gras-Champel V, Liabeuf S (2021) Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®). Bone 153:116137PubMedCrossRef
52.
53.
Yanagisawa K, Ogawa Y, Hosogai M, Todokoro D, Mitsui T, Yokohama A, Kishi S, Handa H (2017) Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. J Infect Chemother 23(8):572–575PubMedCrossRef
54.
Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A (2023) Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflamm 31(5):1079–1080PubMedCrossRef
55.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B (2023) Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis 82(7):901–910. https://​doi.​org/​10.​1136/​ard-2022-223715. (Epub 2023 Mar 17)CrossRefPubMed
Metadaten
Titel
Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
verfasst von
Qianqian Dai
Yanfeng Zhang
Qian Liu
Chijin Zhang
Publikationsdatum
22.03.2024
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 5/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06940-5

Weitere Artikel der Ausgabe 5/2024

Clinical Rheumatology 5/2024 Zur Ausgabe

ORIGINAL ARTICLE

Clinical features and risk factors of primary Sjögren’s syndrome complicated with severe pneumonia: a case–control study

ORIGINAL ARTICLE

Identification of EPSTI1 as a new potential biomarker for SLE based on GEO database

ORIGINAL ARTICLE

Functional capacity, physical activity, and arterial stiffness in patients with systemic sclerosis

REVIEW ARTICLE

How can clinicians enhance self-efficacy beliefs in osteoarthritis? An overview of systematic reviews with meta-analysis

ORIGINAL ARTICLE

Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia

ORIGINAL ARTICLE

Non-thyroidal disease syndrome in patients with systemic lupus erythematosus: relation to disease inflammatory activity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise